☆ 4.7 Article

TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer

Delong Meng et al.

Summary: The study found that complete suppression of mTORC1 using a bi-steric molecule called RMC-6272 induces apoptosis in ER+/HER2- breast cancer cell lines. This molecule is particularly effective in cells with mutations in PIK3CA or PTEN, inhibiting proteins such as 4EBP1 and MCL1 that are associated with mTORC1, leading to cell death. Additionally, RMC-6272 reduces transcription levels of oncogenes, suggesting a greater impact on oncogenic pathways compared to the partial mTORC1 inhibitor everolimus. Selective dual inhibition of mTORC1 may be effective in overcoming therapy resistance in ER+ breast cancers.

ONCOGENE (2023)

Add to Collection

Article Oncology

JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States

Laura E. Stevens et al.

Summary: Inflammatory breast cancer (IBC) is a difficult-to-treat disease with poor clinical outcomes due to high risk of metastasis and resistance to treatment. CD44(+)CD24(-) cells, which possess stem cell-like features, are the most frequent cell type in IBC and are commonly activated by the JAK2/STAT3 signaling pathway. Combination therapy with JAK2/STAT3 inhibition and paclitaxel has shown promising results in decreasing IBC xenograft growth. Furthermore, single-cell analyses have revealed the mechanisms of chemotherapy resistance and the potential of targeting the cAMP/PKA signaling pathway in IBC.

CANCER RESEARCH (2023)

Add to Collection

Review Biochemistry & Molecular Biology

Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data

Federica Villa et al.

Summary: This article reviews the cellular mechanisms, treatment strategies, and clinical data of subsequent treatments after resistance to CDK4/6is-based therapy. It discusses the cell-cycle-specific and cell-cycle-non-specific resistance, focusing on early and late progression. It also analyzes potential therapeutic approaches and available clinical data.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Genetics & Heredity

Identification of hub genes associated with EMT-induced chemoresistance in breast cancer using integrated bioinformatics analysis

Bhavjot Kaur et al.

Summary: This study identified hub genes associated with EMT and chemoresistance in breast cancer, impacting patient survival. The research found that commonly differentially expressed genes (DEGs) were involved in chemoresistance and EMT, and that EMT-induced breast cancer cells exhibited drug efflux transporter overexpression and resistance to chemotherapy. Pathway enrichment analysis revealed enrichment in immunological pathways, early endosome, protein dimerization, and proteoglycans in cancer, and identified eight hub genes from the protein-protein interaction (PPI) network.

GENE (2022)

Add to Collection

Article Chemistry, Multidisciplinary

Harmine is an effective therapeutic small molecule for the treatment of cardiac hypertrophy

Jie Huang et al.

Summary: Harmine exhibits protective effects on cardiac hypertrophy, reducing cell enlargement, restoring calcium handling and contractility, and downregulating hypertrophy-related genes. It also inhibits NF-kappa B phosphorylation and inflammatory cytokines, suggesting it as a promising therapeutic agent for cardiac hypertrophy independent of blood pressure modulation.

ACTA PHARMACOLOGICA SINICA (2022)

Add to Collection

Article Biology

How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story

Viola Cogliati et al.

Summary: CDK4/6 inhibitors in combination with endocrine therapy are the best treatment option for advanced breast cancer. However, the optimal strategy after treatment failure remains unclear. This review analyzes resistance mechanisms and clinical trial results to provide a comprehensive overview.

LIFE-BASEL (2022)

Add to Collection

Review Oncology

Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer

April C. Watt et al.

Summary: Pharmacological inhibitors of CDK4/6 are standard therapies for hormone receptor-positive breast cancer, primarily by suppressing tumor cell proliferation. Recent data suggests that these inhibitors also have other effects in tumor and stromal compartments, which may explain their clinical activity.

BREAST CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells

Ryohei Ogata et al.

Summary: Acquired resistance to PAL or ABE in breast cancer cells confers cross-resistance to the other CDK4/6 inhibitor but not to chemotherapeutic agents. Down-regulation of basal RB expression and normalized RB phosphorylation reduced by CDK4/6 inhibitors may be responsible for the attenuated anti-cell growth effects of the inhibitors.

BREAST CANCER (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Twist1 is required for the development of UVB-induced squamous cell carcinoma

Fernando Eguiarte-Solomon et al.

Summary: The transcription factor Twist1 plays a critical role in regulating the balance between proliferation and differentiation of keratinocytes, impacting the development of UVB-induced skin cancer. Deletion of Twist1 in keratinocytes leads to reduced epidermal hyperproliferation and suppresses skin carcinogenesis caused by UVB radiation, indicating Twist1 as a potential target for preventing cutaneous squamous cell carcinoma.

MOLECULAR CARCINOGENESIS (2021)

Add to Collection

Article Multidisciplinary Sciences

Harmine inhibits breast cancer cell migration and invasion by inducing the degradation of Twist1

Ebtesam Nafie et al.

Summary: The study found that Harmine can inhibit migration and invasion of human and mouse breast cancer cells, possibly by inducing Twist1 degradation. This inhibition is largely independent of its cytotoxicity, but due to its ability to affect EMT regulator Twist1.

PLOS ONE (2021)

Add to Collection

Article Oncology

Cancer statistics for the year 2020: An overview

Jacques Ferlay et al.

Summary: The study briefly reviews the methods and data sources used in compiling the IARC GLOBOCAN cancer statistics for 2020 and summarizes the main results. It estimated that there were nearly 19.3 million new cancer cases and almost 10 million cancer deaths worldwide in 2020, with the most commonly diagnosed cancers being female breast cancer and lung cancer, and the most common causes of cancer death being lung cancer and liver cancer.

INTERNATIONAL JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

Aleix Prat et al.

Summary: This study aimed to evaluate the prognostic and predictive value of intrinsic subtypes in hormone receptor-positive, HER2-negative advanced breast cancer treated with endocrine therapy and ribociclib. The results showed that all intrinsic subtypes except basal-like benefited from ribociclib treatment with consistent PFS improvement.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Dominant role of CDKN2B/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis

Yong Xia et al.

Summary: The human chromosome locus 9p21.3 encodes three CDK inhibitors, among which p15INK4B exhibits stronger inhibitory effects on cell cycle and glycolysis compared to p16INK4A, highlighting its significant role as a tumor suppressor in cancer development.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Dynamic EMT: a multi-tool for tumor progression

Simone Brabletz et al.

Summary: The process of epithelial-mesenchymal transition (EMT) is critical for embryonic development and plays a key role in cancer progression by inducing changes in cell characteristics and motility. Targeting EMT therapeutically could be a promising approach to interfere with tumor progression on multiple levels.

EMBO JOURNAL (2021)

Add to Collection

Meeting Abstract Oncology

Overall survival (OS) with palbociclib (PAL) plus fulvestrant (FUL) in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Updated analyses from PALOMA-3.

Massimo Cristofanilli et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Genetics & Heredity

CEACAM Gene Family Mutations Associated With Inherited Breast Cancer Risk - A Comparative Oncology Approach to Discovery

Anna L. W. Huskey et al.

Summary: This study identified a significant association between CEACAM24 gene mutations and CMT risk in Golden Retrievers. Rare PTVs in the CEACAM gene family were also found in human breast cancer cases, suggesting a potential genetic risk for breast cancer.

FRONTIERS IN GENETICS (2021)

Add to Collection

Article Oncology

Histone Deacetylase Inhibitor-Induced CDKN2B and CDKN2D Contribute to G2/M Cell Cycle Arrest Incurred by Oxidative Stress in Hepatocellular Carcinoma Cells via Forkhead Box M1 Suppression

Hae-Ahm Lee et al.

Summary: HDACi sensitizes HCC cells to oxidative stress by inducing CDK inhibitor expression, leading to inhibition of CDK4/6, FOXM1, and downstream target genes phosphorylation, ultimately causing G2/M cell cycle arrest.

JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer

James R. Whittle et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Decreased ER dependency after acquired resistance to CDK4/6 inhibitors

Masafumi Iida et al.

BREAST CANCER (2020)

Add to Collection

Article Genetics & Heredity

Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+MCF7 Breast Cancer Cells

Lilibeth Lanceta et al.

GENES (2020)

Add to Collection

Article Oncology

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (PALOMA-1, TRIO-18)

Richard S. Finn et al.

BREAST CANCER RESEARCH AND TREATMENT (2020)

Add to Collection

Article Oncology

ΔNp63-Regulated Epithelial-to-Mesenchymal Transition State Heterogeneity Confers a Leader-Follower Relationship That Drives Collective Invasion

Jill M. Westcott et al.

CANCER RESEARCH (2020)

Add to Collection

Article Oncology

Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single-center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database

Hong Yang et al.

ONCOLOGY LETTERS (2020)

Add to Collection

Correction Multidisciplinary Sciences

MiR-31 promotes mammary stem cell expansion and breast tumorigenesis by suppressing Wnt signaling antagonists (vol 8, 1036, 2017)

Cong Lv et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Oncology

Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs

Jennifer L. Green et al.

MOLECULAR CANCER THERAPEUTICS (2019)

Add to Collection

Correction Multidisciplinary Sciences

ΔNp63 to TAp63 expression ratio as a potential molecular marker for cervical cancer prognosis (vol 14, e0214867, 2019)

Sunyoung Park et al.

PLOS ONE (2019)

Add to Collection

Article Multidisciplinary Sciences

p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition

Keelan Z. Guiley et al.

SCIENCE (2019)

Add to Collection

Meeting Abstract Oncology

Inhibition of CDK7 overcomes resistance to CDK4/6 inhibitors in hormone receptor positive breast cancer cells

C. Guarducci et al.

CANCER RESEARCH (2019)

Add to Collection

Article Oncology

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer

Renee de Leeuw et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Mathematical & Computational Biology

Evaluation of Drug Combination Effect Using a Bliss Independence Dose-Response Surface Model

Qin Liu et al.

STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2018)

Add to Collection

Article Oncology

Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer

Sara Redaelli et al.

CANCER RESEARCH (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

C. Yang et al.

ONCOGENE (2017)

Add to Collection

Article Oncology

A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer

Zachary A. Yochum et al.

MOLECULAR CANCER RESEARCH (2017)

Add to Collection

Review Biochemistry & Molecular Biology

Function and Regulation of MicroRNA-31 in Development and Disease

Nadezda A. Stepicheva et al.

MOLECULAR REPRODUCTION AND DEVELOPMENT (2016)

Add to Collection

Article Medicine, General & Internal

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

G. N. Hortobagyi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

Palbociclib and Letrozole in Advanced Breast Cancer

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Review Oncology

Challenges in the management of advanced, ER-positive, HER2-negative breast cancer

Christopher D. Hart et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2015)

Add to Collection

Article Oncology

An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer

Xin Zhou et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2014)

Add to Collection

Article Oncology

Regulatory roles of microRNA-708 and microRNA-31 in proliferation, apoptosis and invasion of colorectal cancer cells

San-Lin Lei et al.

ONCOLOGY LETTERS (2014)

Add to Collection

Article Multidisciplinary Sciences

A preliminary study of the relationship between breast cancer metastasis and loss of heterozygosity by using exome sequencing

Hongsheng Li et al.

SCIENTIFIC REPORTS (2014)

Add to Collection

Article Biotechnology & Applied Microbiology

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

Michael I. Love et al.

GENOME BIOLOGY (2014)

Add to Collection

Article Biochemical Research Methods

STAR: ultrafast universal RNA-seq aligner

Alexander Dobin et al.

BIOINFORMATICS (2013)

Add to Collection

Article Oncology

Spatiotemporal Regulation of Epithelial-Mesenchymal Transition Is Essential for Squamous Cell Carcinoma Metastasis

Jeff H. Tsai et al.

CANCER CELL (2012)

Add to Collection

Review Oncology

Cyclin D as a therapeutic target in cancer

Elizabeth A. Musgrove et al.

NATURE REVIEWS CANCER (2011)

Add to Collection

Editorial Material Oncology

miR-31: a master regulator of metastasis?

Thomas D. Schmittgen

FUTURE ONCOLOGY (2010)

Add to Collection

Article Multidisciplinary Sciences

TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs

Xiaohua Su et al.

NATURE (2010)

Add to Collection

Article Biochemical Research Methods

The Sequence Alignment/Map format and SAMtools

Heng Li et al.

BIOINFORMATICS (2009)

Add to Collection

Article Oncology

Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer

Y Mironchik et al.

CANCER RESEARCH (2005)

Add to Collection

Article Biochemical Research Methods

Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method

KJ Livak et al.

METHODS (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.